Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
30 juil. 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern Time NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a...
Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration for a Novel, Rule-In, Blood Test to Support the Diagnosis of Fibromyalgia
17 juin 2020 08h25 HE
|
Exagen Inc.
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced...
Aptinyx Reports First Quarter 2020 Financial Results and Highlights
14 mai 2020 16h03 HE
|
Aptinyx Inc.
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations...
Axsome Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
08 mai 2020 07h00 HE
|
Axsome Therapeutics, Inc.
Clinical successes highlight Axsome’s accelerated evolution into a leading CNS company Positive pivotal Phase 2/3 results for AXS-05 in Alzheimer’s disease agitation further deepen innovative...
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
30 mars 2020 16h01 HE
|
Aptinyx Inc.
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common...
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020
18 mars 2020 16h01 HE
|
Aptinyx Inc.
EVANSTON, Ill., March 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present at Upcoming Investor Conferences
19 févr. 2020 08h37 HE
|
Aptinyx Inc.
EVANSTON, Ill., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxetine Clinical and Nonclinical Data and for New Phase 3 Esreboxetine Product Candidate
13 janv. 2020 06h00 HE
|
Axsome Therapeutics, Inc.
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy Expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia ...
Aptinyx to Present at 38th Annual J.P. Morgan Healthcare Conference
12 déc. 2019 07h07 HE
|
Aptinyx Inc.
EVANSTON, Ill., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx to Present at Upcoming Investor Conferences
14 nov. 2019 07h57 HE
|
Aptinyx Inc.
EVANSTON, Ill., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...